Identification of Prognostic Biomarkers Among FAM83 Family Genes in Human Ovarian Cancer Through Bioinformatic Analysis and Experimental Verification

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108–121. doi:10.1097/AOG.000000000000417333278287
   PubMed Web of Science ®Google Scholar
• Shimizu A, Sawada K, Kimura T. Pathophysiological role and potential therapeutic exploitation of exosomes in ovarian cancer. Cells. 2020;9(4):814.
   PubMed Web of Science ®Google Scholar
• Rottmann M, Burges A, Mahner S, et al. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol. 2017;143(9):1833–1844. doi:10.1007/s00432-017-2422-628447160
   PubMed Web of Science ®Google Scholar
• Salamini-Montemurri M, Lamas-Maceiras M, Barreiro-Alonso A, et al. The challenges and opportunities of LncRNAs in ovarian cancer research and clinical use. Cancers. 2020;12(4):1020. doi:10.3390/cancers12041020
   PubMed Web of Science ®Google Scholar
• Hongdusit A, Liechty ET, Fox JM. Optogenetic interrogation and control of cell signaling. Curr Opin Biotechnol. 2020;66:195–206. doi:10.1016/j.copbio.2020.07.00733053496
   PubMed Web of Science ®Google Scholar
• Wu J, Jiang H, Luo S, et al. Caspase-mediated cleavage of C53/LZAP protein causes abnormal microtubule bundling and rupture of the nuclear envelope. Cell Res. 2013;23(5):691–704. doi:10.1038/cr.2013.3623478299
   PubMed Web of Science ®Google Scholar
• Bozatzi P, Sapkota GP. The FAM83 family of proteins: from pseudo-PLDs to anchors for CK1 isoforms. Biochem Soc Trans. 2018;46(3):761–771. doi:10.1042/BST2016027729871876
   PubMed Web of Science ®Google Scholar
• Snijders AM, Lee SY, Hang B, Hao W, Bissell MJ, Mao JH. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach. Mol Oncol. 2017;11(2):167–179. doi:10.1002/1878-0261.1201628078827
   PubMed Web of Science ®Google Scholar
• Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA, Jackson MW. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. 2014;12(8):1156–1165. doi:10.1158/1541-7786.MCR-13-028924736947
   PubMed Web of Science ®Google Scholar
• Liu C, Huang XY, Huang Y. FAM83G promotes proliferation, invasion, and metastasis by regulating PI3K/AKT signaling in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2021;567:63–71. doi:10.1016/j.bbrc.2021.05.08134144502
   PubMed Web of Science ®Google Scholar
• Fulcher LJ, Bozatzi P, Tachie-Menson T, et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Sci Signal. 2018;11(531):531. doi:10.1126/scisignal.aao2341
   Web of Science ®Google Scholar
• Lee SY, Meier R, Furuta S, et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest. 2012;122(9):3211–3220. doi:10.1172/JCI6049822886303
   PubMed Web of Science ®Google Scholar
• Cipriano R, Graham J, Miskimen KL, et al. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 2012;122(9):3197–3210. doi:10.1172/JCI6051722886302
   PubMed Web of Science ®Google Scholar
• He S, Wang W, Wan Z, et al. FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway. Oncogenesis. 2021;10(1):6. doi:10.1038/s41389-020-00301-y33423038
   PubMed Web of Science ®Google Scholar
• Zhu H, Diao S, Lim V, Hu L, Hu J. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway. Acta Biochim Biophys Sin. 2019;51(5):509–516. doi:10.1093/abbs/gmz02830939187
   PubMedGoogle Scholar
• Zhang Q, Yu S, Lok SIS, Wong AST, Jiao Y, Lee LTO. FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer. J Cell Mol Med. 2019;23(7):4569–4581. doi:10.1111/jcmm.1436031037837
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180. doi:10.1593/neo.0711217356713
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Cao T, Pan W, Sun X, Shen H. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis. J Ovarian Res. 2019;12(1):101. doi:10.1186/s13048-019-0575-431656201
   PubMed Web of Science ®Google Scholar
• Guo L, Fang T, Jiang Y, Liu D. Identification of immune checkpoint inhibitors and biomarkers among STAT family in stomach adenocarcinoma. Am J Transl Res. 2020;12(9):4977–4997.33042401
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang X, Liu Z, et al. Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. Am J Transl Res. 2020;12(9):5416–5432.33042428
   PubMed Web of Science ®Google Scholar
• Zhao R, Peng C, Song C, et al. BICC1 as a novel prognostic biomarker in gastric cancer correlating with immune infiltrates. Int Immunopharmacol. 2020;87:106828. doi:10.1016/j.intimp.2020.10682832736193
   PubMed Web of Science ®Google Scholar
• Mu Y, Zou H, Chen B, Fan Y, Luo S. FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. Biomed Pharmacother. 2017;90:548–554. doi:10.1016/j.biopha.2017.03.07328407575
   PubMed Web of Science ®Google Scholar
• Bozatzi P, Dingwell KS, Wu KZ, et al. PAWS1 controls Wnt signalling through association with casein kinase 1alpha. EMBO Rep. 2018;19(4):e44807. doi:10.15252/embr.201744807.29514862
   PubMed Web of Science ®Google Scholar
• Cummins TD, Wu KZL, Bozatzi P, et al. PAWS1 controls cytoskeletal dynamics and cell migration through association with the SH3 adaptor CD2AP. J Cell Sci. 2018;131(1):jcs202390.29175910
   PubMed Web of Science ®Google Scholar
• Kweon YS, Lee KE, Ko J, Hu JC, Simmer JP, Kim JW. Effects of Fam83h overexpression on enamel and dentine formation. Arch Oral Biol. 2013;58(9):1148–1154. doi:10.1016/j.archoralbio.2013.03.00123545224
   PubMed Web of Science ®Google Scholar
• Hu H, Wang F, Wang M, et al. FAM83A is amplified and promotes tumorigenicity in non-small cell lung cancer via ERK and PI3K/Akt/mTOR pathways. Int J Med Sci. 2020;17(6):807–814. doi:10.7150/ijms.3399232218702
   PubMed Web of Science ®Google Scholar
• Shen CQ, Yan TT, Liu W, et al. High expression of FAM83B predicts poor prognosis in patients with pancreatic ductal adenocarcinoma and correlates with cell cycle and cell proliferation. J Cancer. 2017;8(16):3154–3165. doi:10.7150/jca.2008629158787
   PubMed Web of Science ®Google Scholar
• Gan J, Li Y, Meng Q. Systematic analysis of expression profiles and prognostic significance for FAM83 family in non-small-cell lung cancer. Front Mol Biosci. 2020;7:572406. doi:10.3389/fmolb.2020.57240633363204
   PubMed Web of Science ®Google Scholar
• Wang D, Han S, Peng R, et al. FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma. Biochem Biophys Res Commun. 2015;458(2):313–320. doi:10.1016/j.bbrc.2015.01.10825646692
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang S, Wei Y, Chen H, Jiao Z, Li Y. Upregulation of family with sequence similarity 83 member D expression enhances cell proliferation and motility via activation of Wnt/beta-catenin signaling and predicts poor prognosis in gastric cancer. Cancer Manag Res. 2019;11:6775–6791. doi:10.2147/CMAR.S20308231413630
   PubMed Web of Science ®Google Scholar
• Zhai X, Yang Z, Liu X, Dong Z, Zhou D. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer. PeerJ. 2020;8:e9975. doi:10.7717/peerj.997533005492
   PubMed Web of Science ®Google Scholar
• Fuziwara CS, Saito KC, Leoni SG, Waitzberg AFL, Kimura ET. The highly expressed FAM83F protein in papillary thyroid cancer exerts a pro-oncogenic role in thyroid follicular cells. Front Endocrinol (Lausanne). 2019;10:134. doi:10.3389/fendo.2019.0013430881348
   PubMed Web of Science ®Google Scholar
• Zhuang H, Zhang C, Hou B. FAM83H overexpression predicts worse prognosis and correlates with less CD8(+) T cells infiltration and Ras-PI3K-Akt-mTOR signaling pathway in pancreatic cancer. Clin Transl Oncol. 2020;22(12):2244–2252. doi:10.1007/s12094-020-02365-z32424701
   PubMed Web of Science ®Google Scholar
• Kim KM, Hussein UK, Bae JS, et al. The expression patterns of FAM83H and PANX2 are associated with shorter survival of clear cell renal cell carcinoma patients. Front Oncol. 2019;9:14. doi:10.3389/fonc.2019.0001430723706
   PubMed Web of Science ®Google Scholar
• Shi R, Sun J, Sun Q, et al. Upregulation of FAM83D promotes malignant phenotypes of lung adenocarcinoma by regulating cell cycle. Am J Cancer Res. 2016;6(11):2587–2598.27904773
   PubMed Web of Science ®Google Scholar
• Kim KM, Park SH, Bae JS, et al. FAM83H is involved in the progression of hepatocellular carcinoma and is regulated by MYC. Sci Rep. 2017;7(1):3274. doi:10.1038/s41598-017-03639-328607447
   PubMed Web of Science ®Google Scholar
• Kim KM, Hussein UK, Park SH, et al. FAM83H is involved in stabilization of beta-catenin and progression of osteosarcomas. J Exp Clin Cancer Res. 2019;38(1):267. doi:10.1186/s13046-019-1274-031215499
   PubMed Web of Science ®Google Scholar
• An Y, Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer. Int J Cancer. 2021;149(1):21–30. doi:10.1002/ijc.3340833231290
   PubMed Web of Science ®Google Scholar
• La Rocca C, Carbone F, Longobardi S, Matarese G. The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol Lett. 2014;162(1 Pt A):41–48. doi:10.1016/j.imlet.2014.06.01324996040
   PubMed Web of Science ®Google Scholar
• Chen F, Xu Y, Chen Y, Shan S. TIGIT enhances CD4(+) regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model. Cancer Med. 2020;9(10):3584–3591. doi:10.1002/cam4.297632212317
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538–18543. doi:10.1073/pnas.050918210216344461
   PubMed Web of Science ®Google Scholar
• Harjunpaa H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078.31231358
   PubMed Web of Science ®Google Scholar
• Liu Z, Shen F, Wang H, et al. Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients. Cell Cycle. 2020;19(13):1632–1640. doi:10.1080/15384101.2020.176203832436804
   PubMed Web of Science ®Google Scholar